![]() ![]() Following her internal medicine residency at Johns Hopkins School of Medicine, she returned to her home state of Texas for oncology fellowship training at MD Anderson. Byers earned her medical degree from Baylor College of Medicine. She also serves on the faculty of MD Anderson UTHealth Graduate School.ĭr. She has a bachelor's in molecular biology from Princeton University and a master's in cancer biology, with a specialization in patient-based research, from The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. ![]() I am trying to change the outcome for patients with this disease.” I have watched too many lung cancer patients die. “Every week I see patients with this disease. Rudin’s complex, multi-pronged attack on lung cancer is based on a very simple idea – saving lives. “Funding from LUNGevity really complements the federal funding system and helps to improve outcomes for lung cancer patients.”ĭr. But that is where organizations like LUNGevity make a large impact. Sadly, there is a huge disparity between lung cancer research funding and research funding for other cancers, such as breast and prostate cancer, says Dr. ![]() The development of detection techniques and therapeutics costs money. “A recent national lung cancer screening trial showed that early detection is possible and it can have an impact on mortality rates, but it’s not enough…We need better, cheaper early detection techniques that can be used to screen all people.” “To really have an impact, early detection is going to be essential,” says Dr. Rudin, a member of LUNGevity’s Scientific Advisory Board, knows that by the time lung cancer is detected, it’s usually too late. Rudin is working to develop therapeutics in the laboratory, he also treats patients on a regular basis. Rudin’s lab is creating real-time, parallel developments in the laboratory and the clinic that may be the foundation for major breakthroughs in lung cancer care. Rudin’s laboratory so that his team can study the effects of the virus on lung cancer and conduct correlative analyses. The blood and tumor samples from this trial are returning to Dr. This groundbreaking work has prompted a national clinical trial to consider the possibility of using this virus to help specifically target and kill lung cancer cells. One of his exciting findings is a virus that targets small cell lung cancer. It is a powerful cycle.Īlready his laboratory has run numerous clinical trials looking at novel therapeutics in lung cancer patients. These techniques are then taken back to the clinic to be tested in patients who are participating in early stage clinical trials. Rudin’s team studies lung cancer and develops novel therapeutics in the lab. ![]() By using fresh tumor samples from the patient clinic across the street from his laboratory, Dr. Rudin utilizes his exceptional skills to effectively blend basic science and translational research. Rudin conducts basic science research, develops cutting edge translational therapeutics, and treats lung cancer patients.Īs Chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, Dr. Rudin is staging a strategic multi-pronged attack on the disease. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |